NICE agrees to look again at Alzheimer's drug Leqembi

Eisai will have an unprecedented third attempt to convince experts at UK medicines cost-effectiveness assessor NICE that the NHS should fund its Biogen-partnered Alzheimer's disease therapy Leqembi.